COX-2-derived prostacyclin modulates vascular remodeling.
about
Soluble epoxide hydrolase inhibition modulates vascular remodelingMeasurement of Reactive Oxygen Species, Reactive Nitrogen Species, and Redox-Dependent Signaling in the Cardiovascular System: A Scientific Statement From the American Heart Association.Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells.Matrix metalloproteinase 2 and 9 dysfunction underlie vascular stiffness in circadian clock mutant mice.Vascular disease in mice with a dysfunctional circadian clockMicrosomal prostaglandin e2 synthase-1 modulates the response to vascular injuryMyeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.Emerging roles of PGE2 receptors in models of neurological disease.Thromboxane and the thromboxane receptor in cardiovascular disease.Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotalineTargeted deletions of cyclooxygenase-2 and atherogenesis in mice.Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Intratracheal administration of cyclooxygenase-1-transduced adipose tissue-derived stem cells ameliorates monocrotaline-induced pulmonary hypertension in ratsThe cycloxygenase 2 (COX-2) story: it's time to explain, not inflame.Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women.Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.Tissue-intrinsic dysfunction of circadian clock confers transplant arteriosclerosis.Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyCardiovascular biology of microsomal prostaglandin E synthase-1.Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening.Analgesic Efficacy of Firocoxib, a Selective Inhibitor of Cyclooxygenase 2, in a Mouse Model of Incisional Pain.Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif.COX-1(+/-)COX-2(-/-) genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI-1.High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cellsAbsence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells.Increased superoxide and endothelial NO synthase uncoupling in blood vessels of Bmal1-knockout mice.Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature.Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanismCD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice.Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractilityCyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice.Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.Activation-dependent stabilization of the human thromboxane receptor: role of reactive oxygen species.Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.Imbalanced synthesis of cyclooxygenase-derived thromboxane A2 and prostacyclin compromises vasomotor function of the thoracic aorta in Marfan syndrome.Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries.Renal and cardiovascular characterization of COX-2 knockdown mice.The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway.Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways.
P2860
Q28394250-AAAD88CF-930D-4AB8-BB1D-469E093A434CQ30248995-5AA34538-7A91-4944-984E-1926BBA14D8BQ30433341-4FD7213A-7AFD-468B-8800-6CD6BC4CFC5EQ30472463-3E0FFE71-C5E9-4D54-8A40-38FA7B1D314CQ30490924-4C114D95-D261-4BCE-8D80-CE1D8B1B220CQ30557273-F98B1543-3C09-4F03-827C-E0C252898DC1Q33607097-E5D5066B-B6FC-4C67-91F2-E451C1232C71Q33756150-9922EFA8-7A5F-4358-A430-F8A730AFB4CAQ33899567-0FF7EC02-AA3F-49E9-8D15-C03D8CCFC1B3Q33995716-0ADED529-D387-4412-919B-8EEE63ED1CADQ34019117-78AD9ED4-155B-4628-B940-FA26CA179548Q34245387-09D67EB6-2E6C-4981-B2C4-6DE9427BD87CQ34356181-9ABBA5CE-76D7-450E-96E4-5AE8D7B943A4Q34636574-67D27781-DECA-4FED-8F4A-3C9943084472Q34827484-FDD0F0F4-4CB1-495D-AE22-0447E0170887Q35029268-495F72EF-2B54-4D9A-BF12-D1B557F4343DQ35345992-82E07DE8-1A7A-4AEC-A15F-1A0F3814BDCCQ35373624-877DA854-84F4-47A9-A173-68C6C70898DEQ35607129-7626FEDB-6090-4C81-9BB7-D906521F0470Q35893373-4B99EA1C-EDA0-4561-B893-E75B3B2BE323Q35906890-7324698F-CE61-43C0-9B19-3AC2E346BA65Q36822598-A8C7640A-23E9-4DCC-9909-AC68716B80CEQ36943451-97F13297-3D3D-481B-AC49-B6D36565B158Q36948503-BEE07CB1-B0F1-42EE-B493-613E5C64EA40Q36982666-9D1A5AE3-6847-41DE-B3FE-808B751CD1CAQ37088422-0661883A-5A12-4101-9ADF-9697EE0983D3Q37106691-A11822C9-042B-4227-B438-39B321BD1E1AQ37233419-10C2AD46-E922-442D-ACD3-08DF30F7A8B1Q37248837-4B4C1905-3A03-4FAB-AF4F-4720E4FAA2B9Q37353551-BB606D53-13FB-45AB-962B-3D482C248C1FQ37735500-CA7333CC-4D20-4014-9A1F-55AA6C4A0270Q38161572-7B55F14F-C034-4AC6-8F21-BFE9A0D39DB9Q39893903-CDE42C7D-6B00-41D2-8B50-0AA201EE6CB7Q41849619-89EE941C-57C0-45EA-BA39-894D92EB38DEQ42028419-3EF6AFE0-698E-406C-AF14-56ABD62BD783Q42114731-9C6B2C78-266A-48AC-B22A-6EC79444F5F9Q43209182-6C9954A1-2C05-4BC7-BB85-49EF9192838FQ46055913-DCFBF1DD-9612-4DFC-8E4D-5D94B523A7CDQ46884698-01042778-9871-4936-8016-6EAC129607B4Q46935186-D91E0E7C-A4A6-4CED-B0CB-F6D48E8F0486
P2860
COX-2-derived prostacyclin modulates vascular remodeling.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
COX-2-derived prostacyclin modulates vascular remodeling.
@en
COX-2-derived prostacyclin modulates vascular remodeling.
@nl
type
label
COX-2-derived prostacyclin modulates vascular remodeling.
@en
COX-2-derived prostacyclin modulates vascular remodeling.
@nl
prefLabel
COX-2-derived prostacyclin modulates vascular remodeling.
@en
COX-2-derived prostacyclin modulates vascular remodeling.
@nl
P2093
P1433
P1476
COX-2-derived prostacyclin modulates vascular remodeling
@en
P2093
Derek Brinster
Garret A FitzGerald
Sandra Austin
Susanne Fries
Thomas M Coffman
P304
P356
10.1161/01.RES.0000170888.11669.28
P577
2005-05-19T00:00:00Z